Retention rates of infliximab and tocilizumab during a 3-year period in a Brazilian hospital.
OBJECTIVE
To compare the efficacy and the period of use of tocilizumab and infliximab during treatment of rheumatoid arthritis patients.


METHODS
The period of use of two biologics with different mechanisms of action were compared in treatment of rheumatoid arthritis patients.


RESULTS
Both medications showed efficacy, but the period of use with no loss of efficacy was longer in patients receiving tocilizumab when compared to infliximab.


CONCLUSIONS
Tocilizumab maintains a period of use significantly longer as compared with infliximab in patients with rheumatoid arthritis treated at a single organization.
Ricardo Prado
RP
Golmia
Morton Aaron
MA
Scheinberg
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001691:Biological Therapy; D001938:Brazil; D006801:Humans; D000069285:Infliximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000069285:Infliximab; C502936:tocilizumab